What is the 13F Pro Quality Score for GH?

13F Pro ranks Guardant Health, Inc. (GH) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GH's current score at https://13fpro.ai/company/GH (free sign-up required for the full ranking).

Which hedge funds own the most GH stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of GH include BlackRock,, PRICE T ROWE ASSOCIATES /MD/, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/GH as soon as new 13F filings post.

Where does 13F Pro source GH data?

All Guardant Health, Inc. fundamentals and ownership data come directly from SEC EDGAR. Guardant Health, Inc. files with the SEC under CIK 1576280. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GH in?

Guardant Health, Inc. (GH) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GH research updated on 13F Pro?

GH's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Guardant Health, Inc.(GH)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqlarge

Institutional-grade research for retail investors

SEC EDGAR: CIK 1576280 GH stock profile & AI dashboard →

13F Pro Quality Score

39.0/100

Rank #2,164 of 2,961 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

90.6/100

Profitability

13.1/100

Balance Sheet

8.3/100

Earnings Quality

36.5/100

Free Cash Flow

12.7/100

Institutional Flow

46.8/100

Revenue Scale

53.2/100

Dilution Risk

10.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why GH Scores 39/100

exact factor attribution · 2026-09-11

GH's composite is driven by revenue growth, held back by free cash flow and profitability. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+8.1 pts

91th pct

Scale

+0.5 pts

53th pct

Institutional flow

-0.2 pts

47th pct

Earnings growth

-0.8 pts

33th pct

Earnings quality

-1.4 pts

37th pct

Shareholder dilution

-2.0 pts

11th pct

Capital efficiency

-4.2 pts

8th pct

Profitability

-5.5 pts

13th pct

Free cash flow

-5.6 pts

13th pct

Latest change (2026-08-02): 36 → 35 · ↓ Revenue growth 88→78

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

GH Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Guardant Health, Inc. (GH), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GH at 39.0/100 on a 32-signal composite quality model, placing it at rank #2,164 of 2,961 stocks — the bottom half of the AI-ranked universe. GH scores in the top quartile across revenue growth (90.6). Areas of concern include balance sheet strength (8.3) and free cash flow (12.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 10.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Guardant Health, Inc. reports quarterly revenue of $335.0M, net income of $-120.1M, an operating margin of -38.6%. Top institutional holders of GH by reported 13-F value include BlackRock, PRICE T ROWE ASSOCIATES, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. GH trades on the Nasdaq exchange and files with the SEC under CIK 1576280. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Guardant Health, Inc. directly from SEC EDGAR. Guardant Health, Inc.'s 13F Pro composite quality score has ranged between 30 and 39 since 2021, currently 39.0 — a stable long-term trajectory across 68 quarterly and live scoring snapshots.

Revenue

Q2 2026

$335.0M

Net Income

Q2 2026

$-120.1M

Free Cash Flow

Q2 2026

$-69.5M

Operating Margin

Q2 2026

-38.6%

ROIC

Q2 2026

-40.4%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+32.9% YoY

$982.0MFY 2025

FY22 $449.5MFY23 $563.9MFY24 $739.0MFY25 $982.0M

Net Income

+4.6% YoY

$-416.3MFY 2025

FY22 $-654.6MFY23 $-479.4MFY24 $-436.4MFY25 $-416.3M

Operating Income

+1.4% YoY

$-437.2MFY 2025

FY22 $-544.4MFY23 $-564.7MFY24 $-443.6MFY25 $-437.2M

EPS (Diluted)

+6.7% YoY

$-3.32FY 2025

FY22 $-6.41FY23 $-4.28FY24 $-3.56FY25 $-3.32

Total Assets

+35.5% YoY

$2.01BFY 2025

FY22 $1.61BFY23 $1.79BFY24 $1.49BFY25 $2.01B

Total Debt

+31.6% YoY

$1.50BFY 2025

FY22 —FY23 —FY24 $1.14BFY25 $1.50B

Op. Cash Flow

+23.0% YoY

$-184.8MFY 2025

FY22 $-309.5MFY23 $-325.0MFY24 $-239.9MFY25 $-184.8M

Free Cash Flow

+15.2% YoY

$-233.1MFY 2025

FY22 $-386.9MFY23 $-345.5MFY24 $-274.9MFY25 $-233.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$982.0M +32.9%	$739.0M +31.0%	$563.9M +25.5%	$449.5M +20.3%	$373.7M +30.3%	$286.7M
Net Income	$-416.3M +4.6%	$-436.4M +9.0%	$-479.4M +26.8%	$-654.6M -70.1%	$-384.8M	—
Operating Income	$-437.2M +1.4%	$-443.6M +21.4%	$-564.7M -3.7%	$-544.4M -32.5%	$-411.0M -61.2%	$-254.9M
EPS (Diluted)	$-3.32 +6.7%	$-3.56 +16.8%	$-4.28 +33.2%	$-6.41 -60.3%	$-4.00 -53.8%	$-2.60
Total Assets	$2.01B +35.5%	$1.49B -16.8%	$1.79B +11.0%	$1.61B -27.0%	$2.20B -3.0%	$2.27B
Total Debt	$1.50B +31.6%	$1.14B	—	—	—	—
Operating Cash Flow	$-184.8M +23.0%	$-239.9M +26.2%	$-325.0M -5.0%	$-309.5M -48.1%	$-209.0M -101.1%	$-103.9M
Free Cash Flow	$-233.1M +15.2%	$-274.9M +20.4%	$-345.5M +10.7%	$-386.9M -36.2%	$-284.1M -102.7%	$-140.1M

Get alerted when GH's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Guardant Health, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GH

BlackRock, Inc.
$1.1B7,622,935 sh
PRICE T ROWE ASSOCIATES INC /MD/
$977.4M6,514,952 sh
VANGUARD CAPITAL MANAGEMENT LLC
$863.6M5,755,857 sh
FMR LLC
$823.4M5,488,272 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$817.0M5,445,785 sh
Invesco Ltd.
$664.6M4,429,755 sh
GOLDMAN SACHS GROUP INC
$566.5M3,775,895 sh
TWO SIGMA INVESTMENTS, LP
$558.0M3,719,301 sh
LINDEN ADVISORS LP
$514.2M204,330,000 sh
Capital International Investors
$510.0M3,399,604 sh

Fund	Value	Shares
BlackRock, Inc.	$1.1B	7,622,935
PRICE T ROWE ASSOCIATES INC /MD/	$977.4M	6,514,952
VANGUARD CAPITAL MANAGEMENT LLC	$863.6M	5,755,857
FMR LLC	$823.4M	5,488,272
VANGUARD PORTFOLIO MANAGEMENT LLC	$817.0M	5,445,785
Invesco Ltd.	$664.6M	4,429,755
GOLDMAN SACHS GROUP INC	$566.5M	3,775,895
TWO SIGMA INVESTMENTS, LP	$558.0M	3,719,301
LINDEN ADVISORS LP	$514.2M	204,330,000
Capital International Investors	$510.0M	3,399,604

Companies Similar to GH

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

BBIO

BridgeBio Pharma, Inc.

AI score

Very similar · 33 shared holders

LINDEN ADVISORS LP Hood River Capital Management LLC LORD, ABBETT & CO. LLC

MIRM

Mirum Pharmaceuticals, Inc.

AI score

Very similar · 32 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC EVENTIDE ASSET MANAGEMENT, LLC LORD, ABBETT & CO. LLC

TWST

Twist Bioscience Corp

AI score

Very similar · 22 shared holders

Artisan Partners Limited Partnership WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC BAILLIE GIFFORD & CO

MDGL

MADRIGAL PHARMACEUTICALS, INC.

AI score

Very similar · 23 shared holders

RTW INVESTMENTS, LP WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC LORD, ABBETT & CO. LLC

ADPT

Adaptive Biotechnologies Corp

AI score

Very similar · 20 shared holders

WESTFIELD CAPITAL MANAGEMENT CO LP DRIEHAUS CAPITAL MANAGEMENT LLC LORD, ABBETT & CO. LLC

WGS

GeneDx Holdings Corp.

AI score

Very similar · 14 shared holders

WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC ARK Investment Management LLC First Light Asset Management, LLC

IRTC

iRhythm Holdings, Inc.

AI score

Very similar · 26 shared holders

RTW INVESTMENTS, LP Artisan Partners Limited Partnership EVENTIDE ASSET MANAGEMENT, LLC

INSM

INSMED Inc

AI score

Very similar · 21 shared holders

Capital International Investors RTW INVESTMENTS, LP Artisan Partners Limited Partnership

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GH on your watchlist

Track score changes the day Guardant Health, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GH a good stock to buy?

13F Pro's AI-powered analysis of Guardant Health, Inc. (GH) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GH are available on the GH stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. GH is classified as a large company.

Which hedge funds own GH?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GH. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Guardant Health, Inc.'s investment landscape.